These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 29895964)

  • 1. Tau-targeting therapies for Alzheimer disease.
    Congdon EE; Sigurdsson EM
    Nat Rev Neurol; 2018 Jul; 14(7):399-415. PubMed ID: 29895964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau-targeting therapies for Alzheimer disease: current status and future directions.
    Congdon EE; Ji C; Tetlow AM; Jiang Y; Sigurdsson EM
    Nat Rev Neurol; 2023 Dec; 19(12):715-736. PubMed ID: 37875627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tau protein in Alzheimer's disease.
    Gong CX; Grundke-Iqbal I; Iqbal K
    Drugs Aging; 2010 May; 27(5):351-65. PubMed ID: 20450234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives.
    Suzuki N; Hatta T; Ito M; Kusakabe KI
    Chem Pharm Bull (Tokyo); 2024; 72(7):602-609. PubMed ID: 38945936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
    Sigurdsson EM
    Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
    Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
    J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β-independent regulators of tau pathology in Alzheimer disease.
    van der Kant R; Goldstein LSB; Ossenkoppele R
    Nat Rev Neurosci; 2020 Jan; 21(1):21-35. PubMed ID: 31780819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complexity of tau in Alzheimer's disease.
    Naseri NN; Wang H; Guo J; Sharma M; Luo W
    Neurosci Lett; 2019 Jul; 705():183-194. PubMed ID: 31028844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.